Introduction
The retinoids, natural and synthetic analogs of vitamin A, have diverse biological eects on development, growth and dierentiation of normal and neoplastic cells (Gudas et al., 1994) . Retinoid biological actions are mediated through the nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR) and their co-regulators (Giguere et al., 1987; Mangelsdorf et al., 1990 Mangelsdorf et al., , 1991 Petkovich et al., 1987; Kastner et al., 1997; Nagpal et al., 1992) . Using as models the multipotent human embryonal carcinoma cell line, NTERA-2 clone D1 (NT2/D1), which is sensitive to all-trans retinoic acid (RA)-treatment and its RA-resistant derived line, NT2/D1-R1, a role for speci®c retinoid receptors in tumor cell dierentiation was uncovered. RA-treatment of NT2/ D1 cells signals growth suppression, reduced tumorigenicity, and induced terminal neuronal differentiation (Dmitrovsky et al., 1990) . RA-treatment of NT2/ D1 cells induces RARa, RARb, RARg but not RXRa mRNA expression (Kurie et al., 1993; Moasser et al., 1995a) . Terminal dierentiation of NT2/D1 cells is induced by over-expression of RARg while no maturation or growth suppressive eects were observed with RARa, RARb or RXRa over-expression (Moasser et al., 1995a) . In contrast, NT2D1-R1 cells are unresponsive to RA-treatments (Moasser et al., 1996) . Repressed RARg expression causes retinoid resistance in NT2/D1-R1 cells (Moasser et al., 1994) and RA-response is restored following RARg introduction into NT2/D1-R1 cells (Moasser et al., 1994 (Moasser et al., , 1995a . RARg over-expression in NT2/D1 cells does not trigger the full RA-response, indicating another transcription factor cooperates with RARg. Recently, RXRb was shown to cooperate with RARg in NT2/ D1 cells to signal retinoid response in these cells (Spinella et al., 1998) .
N-(4-hydroxyphenyl)retinamide (4HPR) is a retinoid under active study in several tumor cell contexts (Dowlatshahi et al., 1989; Moon et al., 1992; Bhatnagar et al., 1991; Oridate et al., 1997) and experimental cancers in animal models (Moon et al., 1979; Formelli et al., 1996; Pollard and Luckert, 1991) . 4HPR chemoprevention trials in breast cancer (De Palo et al., 1997) and other epithelial malignancies are underway. The observed 4HPR biological eects on tumor cell growth are reported to result from the triggering of programmed cell death (apoptosis) in diverse cellular contexts (Lotan, 1995) . In contrast to the known biological functions of RA (Gudas et al., 1994; Giguere et al., 1987; Mangelsdorf et al., 1990; Petkovich et al., 1987) , the mechanisms of 4HPR action are less well understood. 4HPR is proposed to signal eects through an RARg dependent-pathway (Fanjul et al., 1996; Kazmi et al., 1996) . 4HPR-treatment is reported to preferentially induce RARg mRNA expression and transcriptional activity (Fanjul et al., 1996) . Others reported that 4HPR functions independent of the retinoid pathways (Delia et al., 1993) , by generating reactive oxygen species that induce apoptosis (Oridate et al., 1997; Delia et al., 1997 ). 4HPR appears to be a poor dierentiation inducer when compared to RA-treatment of HL-60 myeloid leukemia cells (Fontana et al., 1986) . Notably, 4HPR triggers apoptosis even in RA-resistant HL-60 myeloid leukemia cells that contain a mutant RARa (Delia et al., 1993) . This is consistent with the notion that 4HPR functions independent of retinoid receptor pathways.
This study reports that RARg2, not RARg1, is induced by RA-treatment of NT2/D1 cells, while NT2/ D1-R1 cells basally expressed RARg1 with no RARg2 induction following RA-treatment. This highlights a key role for RARg2 in NT2/D1 retinoid response. The data reported in this study comparing the transcriptional properties of cloned RARg species and RARg2 promoter elements from NT2/D1 and independently from NT2/D1-R1 cells indicate that a preferential RARg transcriptional block is present in NT2/D1-R1 cells. This aords a unique opportunity to study the role of 4HPR in the growth and maturation response of retinoid-resistant cells having an RARg transcriptional block to determine whether RARg is required to transmit 4HPR signals. Evidence presented in this study indicates an RARg dependency for terminal dierentiation of human embryonal carcinoma cells, but that 4HPR signaling of apoptosis is RARg independent.
Results
The RARg2 transcript induction after RA-treament of NT2/D1 but not NT2/D1-R1 cells Over-expression of RARg results in growth suppression and maturation of the NT2/D1 multipotent human embryonal carcinoma cell line (Moasser et al., 1995a) , indicating an important role for RARg expression in human embryonal carcinoma dierentiation. Since the two isoforms of RARg are regulated by distinct promoters (Lehmann et al., 1991) , it was important to distinguish which isoform is induced in NT2/D1 cells and which fails to be induced after RA-treatment of NT2/D1-R1 cells. Figure 1a depicts the kinetics of RARg1 and RARg2 mRNA expression in NT2/D1-R1 cells and NT2/D1 cells exposed to 10 mM RA. RARg1 mRNA was basally detected but not induced by RAtreatment in NT2/D1-R1 cells at the times examined. Basal RARgl expression was higher in NT2/D1 cells than in NT2/D1-R1 cells and was not induced by RAtreatment in NT2/D1 cells (Figure 1a and b) . Despite RA-treatment, RARg2 mRNA was undetected in NT2/ D1-R1 cells, while NT2/D1 cells expressed low levels of RARg2 mRNA and 10 mM RA-treatment augmented RARg2 expression (Figure 1a and b) . This induction of RARg2 mRNA in RA-treated NT2/D1 cells was con®rmed by Northern analysis of poly (A) + RNA isolated from NT2/D1 cells treated with or without RA and probed with an end-labeled oligonucleotide hybridized to the unique NH 2 terminus of the RARg2 mRNA (data not shown).
Isolation and characterization of the RA response element present in the RARg promoter region of NT2/ D1-R1 cells
To address whether the aberrant RARg expression was due to cis-or trans-activating mechanisms, a 1.8 kb RARg promoter region was isolated from NT2/D1 cells and from NT2/D1-R1 cells by PCR ampli®cation of genomic DNA. This region was shown to contain the transcriptional start site and RA-responsive region of the RARg2 promoter (Lehmann et al., 1992) . Sequence analysis of the retinoic acid response element (Figure 2 ). However, neither of these RARg2 promoter reporter constructs were transcriptionally activated in NT2/ D1-R1 cells, despite RA-treatment (Figure 3a ). An RARg-selective transcriptional block was con®rmed as present in NT2/D1-R1 cells, since a block in RARb transcription is not found using the RARb 2 promoter in these transfected cells (data not shown and Spinella et al., 1998) . A mutation present in either RARg1 or RARg2 might contribute to RA resistance in NT2/D1-R1 cells. To address this possibility, co-transfection experiments were independently performed in these human embryonal carcinoma cells in the presence and absence of increasing RA dosages using RARg1 and RARg2 wildtype receptors and a 1.8 kb RARg2 promoter element containing reporter. The RA-resistant NT2/D1-R1 cells exhibited reduced promoter transcriptional activities for both RARg1 and RARg2 transfection experiments, while both receptors readily transactivated an RARg2 promoter in the retinoid sensitive NT2/D1 cells following RA-treatment (Figure 3b ). These results are consistent with the view that failure of NT2/D1-R1 cells to respond to RA-treatment was not due to alterations in the indicated RARg promoter region or in RARg itself. The defect responsible for the RA- promoter-enhancer driven control plasmid, pGL3-control. Luciferase activities were normalized to both b-galactosidase activity and the luciferase activity of the pGL3-control for each cell line. Transfectants were treated with the indicated dosages of RA for 24 h. Experiments were performed twice and in duplicate. These experiments identify an RARg transcriptional repression present in NT2/D1-R1 but not NT2/D1 cells resistant phenotype might depend on co-factors of the transcription complex (co-activators and/or co-repressor) or the state of histone acetylation as reported in other RA-resistant human tumor cells (Grignani et al., 1998) . Trichostatin A (TSA), a histone deacetylase inhibitor, was incubated at 25 and 50 nM dosages in combination with 10 mM RA-treatment in transient transfection experiments using NT2/D1-R1 cells and the RARg2 promoter reporter in an attempt to reverse the observed suppression of RARg transcription. TSAtreatment, even when combined with RA-treatment, did not induce promoter reporter activity in NT2/D1-R1 cells (data not shown), indicating that histone deacetylase is not likely involved in this repression.
RARg activation preferentially mediates neuronal dierentiation in human embryonal carcinoma cells
Prior work indicated RARg plays an important role in retinoid mediated NT2/D1 cell dierentiation (Moasser et al., 1994 (Moasser et al., , 1995a Spinella et al., 1998) . However, these studies involved RARg over-expression in NT2/ D1 and NT2/D1-R1 cells. Since over-expression of a nuclear receptor can lead to non-speci®c eects due to squelching of RXRs or co-activators and co-repressors, independent veri®cation of an important role for RARg in human embryonal carcinoma dierentiation was sought.
The key role for RARg in mediating neuronal dierentiation of NT2/D1 cells was con®rmed using retinoid receptor selective agonists and antagonists. Induced neuronal dierentiation of retinoid treated NT2/D1 cells was measured by¯uorescent activated cell sorter (FACS) analysed expression of the neuronal epitope recognized by the A2B5 monoclonal antibody. The RARg selective agonist (10 mM, BMS-185354) induced expression of the neuronal marker A2B5 in NT2/D1 cells as did RA-treatment (Table 1 ). An RARb agonist (BMS-185411), an RARa/b agonist (BMS-191681), a pan-antagonist (BMS-204701) and an RXR agonist (BMS-188649) each failed to induce neuronal dierentiation in NT2/D1 cells at doses as high as 10 mM, as displayed in Table 1 . The ability of RA and BMS-185354 to induce the expression of the A2B5 neuronal marker was reduced and abolished, respectively, in the presence of equimolar concentration of the RAR pan-antagonist (BMS-204701). None of these ligands induced dierentiation in the RA resistant NT2/D1-R1 cells (data not shown). TSA was also evaluated in dierentiation studies of NT2/D1-R1 cells to learn whether the histone deacetylase inhibitor overcomes the dierentiation block observed in these retinoid resistant cells. No induction of the A2B5 dierentiation marker was observed in NT2/D1-R1 cells after treatment with sublethal doses (30 or 40 nM) or acute (24 h) exposure to lethal doses (50, 75 or Experiments were performed twice in duplicate. These studies indicate that the RARg agonist represses transcription of the FGF4 promoter-enhancer reporter and stimulates transcription of the RARg2 promoter reporter. Both of these transcriptional events are known to be tightly coupled to eective retinoid dierentiation response in human embryonal carcinomas 100 nM) of TSA alone or in combination with RAtreatment (5 mM) (data not shown).
To con®rm independently that this retinoid is a speci®c RARg agonist, transient transfection experiments were conducted in NT2/D1 cells using either an RARg2 promoter reporter or the dierentiation state dependent FGF4 promoter-reporter assay previously developed (Moasser et al., 1994; Spinella et al., 1998) to assess dierentiation-dependent signals in human embryonal carcinoma cells. As expected, the RARg agonist (BMS-185354) induced RARg2 promoter reporter activity in a dose-dependent manner which was similar to that observed following RA-treatment (compare Figure 2 and Figure 4a) . In contrast, transcriptional activity from the FGF4 promoter reporter decreased as the dosages of the RARg agonist increased (Figure 4b ). This assay con®rms that NT2/ D1 cells have undergone maturation induced by the RARg agonist since the FGF4 promoter reporter activity repression is an established marker of effective retinoid mediated dierentiation of human embryonal carcinoma cells (Spinella et al., 1998) . As expected, RARb and RARa/b agonists were ineective in either activating transcription of the RARg2 promoter reporter, or suppressing the FGF4 promoter reporter activity (data not shown).
4HPR-induced growth suppression and apoptosis in NT2/D1 and NT2/D1-R1 cells 4HPR is a potent inhibitor of proliferation for both NT2/D1 and the RA resistant NT2/D1-R1 cells. Growth of both of these cell lines was suppressed by more than 50% (as compared to controls) after 3 days of exposure to 1 mM 4HPR (Figure 5a and b) . Inhibition of NT2/D1 cell growth by 4HPR was more rapid than that seen following RA-treatment where 9 days of 5 mM RA-treatment was required to reduce growth to less than 50% of control cells (Fontana et al., 1986; Miller et al., 1994 , and data not shown). RAtreatment had no appreciable eect on NT2/D1-R1 cell growth (Moasser et al., 1996 , and data not shown). Due to an ecient initiation of a cell death program by 4HPR, the dierentiation-inducing ability of 4HPR could only be assessed at the 1 mM dosage in NT2/D1 cells. The percentages of 4HPR-induced dierentiation in NT2/D1 and NT2/D1-R1 cells were essentially the same as for control cells (Table 1 and (®lled symbols) from 6 ± 96 h. Adherent cells were collected and an in situ TDT assay was performed as described (NasonBurchenal et al., 1998) . This result is representative of ®ve independent experiments 4HPR and human embryonal carcinoma differentiation S Kitareewan et al To determine whether 4HPR-treatment in¯uences expression of RARg, an RT ± PCR assay was performed using total RNA independently isolated from NT2/D1 and NT2/D1-R1 cells treated with 1.5 mM of 4HPR for varying lengths of time. Figure  8 revealed that expression of RARg2 was undetected and low expression of RARg1 was observed in 4HPR-treated NT2/D1-R1 cells. Similar ®ndings were found for these RA-treated cells in the experiment depicted in Figure 1a . NT2/D1 cells expressed RARg1 and RARg2 at levels much higher than those detected in NT2/D1-R1 cells, as displayed in Figures 1a and 8 . These species were uninduced following 4HPR-treatment at the indicated dosages and times (Figure 8 ). Quantitation of intensity of each species was normalized for bactin expression.
Discussion
This study investigated RARg dependent mechanisms active in retinoid growth and dierentiation responses in human embryonal carcinoma cells. This study extends prior work by employing as a pharmacological probe in analysis of retinoid response of human embryonal carcinoma cells, an RARg selective agonist. Results were compared to those obtained using other retinoid receptor selective agonists and antagonist.
The lack of RA response in NT2/D1-R1 cells is not due to a decreased permeability of RA into these cells since RA is shown to induce transcription of a heterologous bRARE promoter reporter plasmid in transient transfections of NT2/D1-R1 cells (Kurie et al., 1993; Spinella et al., 1998 , and data not shown). The bRARE promoter activity may be trans-activated by RARb and RARa which are expressed at similar levels as present in RA sensitive NT2/D1 cells (Moasser et al., 1996) . However, when a 1.8 kb native RARg2 promoter was cloned into a reporter plasmid, detected transcriptional activity was minimal in NT2/ D1-R1 cells, as compared to parental NT2/D1 cells (Figure 3a) . Results displayed in Figure 3a and b suggested defect(s) other than the RARg2 promoter and endogenous RARg are responsible for retinoid resistance in NT2/D1-R1 cells.
The RA resistance observed in NT2/D1-R1 cells may result from multiple defects. For example, an altered retinoid receptor-speci®c auxiliary protein could prevent the receptor-ligand complex from activating RARg2 transcription. This auxiliary protein is not required when the RARE is driven by another promoter, e.g., thymidine kinase promoter. This view is supported by reports that a putative`labile' transcriptional repressor protein(s) interacts with RARs and RXRs, (Spanjaard et al., 1997; Cliord et al., 1990) which may be speci®cally required by RARg and its promoter for transcriptional activation. A recent publication by Lin et al. (1998) reported that RA resistance in NB4 acute promyelocytic leukemia cells is conferred by a single mutation in the ligand binding domain of PML-RARa. This mutation blocks RA-mediated dissociation of the co-repressor, SMRT and prevents activation of retinoid target genes. A similar ®nding in RA-resistant PLZF-RARa expressing APL cells is reported (Grignani et al., 1998) where RA does not relieve the inhibitory eects of histone deacetylation mediated by the PLZF-nuclear corepressor, N-CoR complex. This is proposed to cause an RA-resistant leukemic cell phenotype. Resistance to RA-treatment of NT2/D1-R1 cells might also result from a defect in the histone acetyltransferase pathway. A recent report by Kawasaki et al. (1998) indicates that destruction of p300 by hammerhead ribozymes in embryonal carcinoma F9 cells conferred RA resistance. Identi®cation of component(s) responsible for the RA resistant phenotype in NT2/D1-R1 cells is the subject of future work in these and other human embryonal carcinoma cells. Figure 8 The RARg1 and RARg2 mRNA expression in NT2/D1 and NT2/D1-R1 cells treated with 4HPR. The ethidium bromide stained RARg1, RARg2 and b-actin PCR products isolated before and after 4HPR-treatment were independently resolved on an 1.5% agarose gel. RA-sensitive NT2/D1 and RA-resistant NT2/D1-R1 cells were cultured in media containing 1.5 mM 4HPR. Total cellular RNA was isolated, reverse transcribed and ampli®ed for RARg1, RARg2 and b-actin genes, as described in Materials and methods. This study indicates that 4HPR-treatment signals its eects in NT2/D1 and NT2/D1-R1 cells, without inducing RARg species 4HPR and human embryonal carcinoma differentiation S Kitareewan et al A functional overlap is reported to exist between RARg1 and RARg2, but RARg1 appears as the major isoform functioning during development (Subbarayan et al., 1997 ). RARg2 appears required for primitive endodermal dierentiation of murine embryonal carcinoma F9 cells where phosphorylation of AF-1 and AF-2 domains are required (Taneja et al., , 1997 . Using retinoid selective agonists, RARg is observed to mediate dierentiation of S91 melanoma cells (Spanjaard et al., 1997) and re-introduction of RARg into a human squamous cell carcinoma line (SCC 12F) restores RA-signaling dierentiation (Monzon et al., 1997) . These reports are consistent with the ®ndings reported here that indicate a major dierentiation-inducing role for RARg in human embryonal carcinoma cells. Only the RARg selective agonist (BMS-185354) and RA, which is a pan-agonist for retinoid receptors, induced dierentiation in NT2/ D1 cells (Table 1 ). The RARa/b agonist BMS-191681 which is reported to have similar potency as RA in induction of NB4 cells dierentiation (Chen et al., 1996) , failed to initiate dierentiation in NT2/D1 cells (Table 1) . This failure could be accounted for by the known RARg antagonist activity of BMS-191681 (Chen et al., 1996) . RARg2 is the likely isoform signaling these eects in these tumor cells since it is the only RARg species that was inducible by RAtreatment. This result and those obtained by others using targeted murine embryonal carcinoma and embryonal stem cells indicate distinct functional roles for the RARs subtypes and isoforms (Subbarayan et al., 1997; Boylan et al., 1993 Boylan et al., , 1995 .
4HPR is a retinoid reported to signal its actions through an RARg dependent pathway (Fanjul et al., 1996) . Its potential to trigger growth suppression may relate to its ability to initiate apoptosis. In transient transactivation assays in CV-1 cells, 4HPR is reported as an RARg-selective transactivator of the TRE-tk-CAT promoter reporter plasmid and depending on the nature of the response elements used, it may enhance or reduce promoter activities (Fanjul et al., 1996) . RARg mRNA expression increased following 10 mM of 4HPR treatment of CV-1 and MCF-7 cells, by 1.4-and 1.8-fold, respectively. Others (Delia et al., 1993 (Delia et al., , 1997 Sheikh et al., 1995) report that 4HPR signals eects through retinoid receptor independent pathways. This indicated a need to better understand involved mechanisms. It is reported that 4HPR induces apoptosis by generating reactive oxygen species, independent of signaling through retinoid receptors (Oridate et al., 1997; Delia et al., 1997) . Whether generation of reactive oxygen species in NT2/D1 and NT2/D1-R1 cells signals apoptosis or growth suppression in these cells is the subject of future work.
The current study used NT2/D1-R1 cells as a model to explore whether 4HPR induced apoptosis required RARg since these cells have repressed RARg expression and transcription. 4HPR was observed as a potent growth inhibitor in RA sensitive NT2/D1 and RA resistant NT2/D1-R1 cells, as displayed in Figure 5 . The eect of 4HPR on NT2/D1-R1 growth is evident by 24 h of incubation with 4HPR (1 mM) while there was not appreciable growth suppression of NT2/D1 cells observed at any examined 4HPR dosage used during the ®rst 24 h of treatment (see Figure 5 ). TdTdependent apoptosis assays con®rmed the ®nding that RA resistant NT2/D1-R1 cells were more responsive to 4HPR generated apoptotic signals than NT2/D1 cells ( Figure 6 ). These results showed aberrant RARg transcription does not aect apoptotic signals generated by 4HPR treatment of NT2/D1-R1 cells, indicating that 4HPR signals its biologic eects via an RARg independent pathway in human embryonal carcinoma cells. Of note, co-treatment with equimolar of an RAR pan-antagonist (BMS-204701) failed to prevent 4HPR induced apoptosis in either cell line, as shown in Figure 7 . Our results are consistent with a recent report (Cliord et al., 1999) that 4HPR induces growth inhibition and apoptosis of murine embryonal carcinoma cells lacking RARg, RXRa or both of these receptors.
In summary, this study found that 4HPR is a potent inhibitor of growth in retinoid sensitive and resistant human embryonal carcinoma lines. This repression of proliferation is independent of RARg and the signaling of tumor cell maturation. Metastatic germ cell tumors are often cured by treatment with cis-platin based chemotherapy, although cis-platin resistance (Bosl et al., 1997) and RA-resistant germ cell tumors exist (Moasser et al., 1995b (Moasser et al., , 1996 . Recently, NT2/D1-R1 cells were shown to have dual resistance to cis-platin and RA (Spinella et al., unpublished data) . The current study reports that 4HPR triggers apoptosis in NT2/D1-R1 cells that are known to be dually resistant to RA and cis-platin. This ®nding provides a strong rationale for a potential therapeutic role for 4HPR in the management of chemotherapy-resistant germ cell tumors, even when a maturation block is present in these cells.
Materials and methods

Chemicals
The following retinoids were used in this study: BMS-191681, -185354, -204701, -185411 and -188649 , which were obtained from Bristol-Myers Squibb Pharmaceutical Research Institute. 4HPR and TSA were purchased from Biomol Research Laboratories, Inc., (PA, USA) and RA was purchased from Sigma (St. Louis, MO, USA). Each of these retinoids were dissolved in DMSO as 10 mM stock solutions and stored in the dark at 7708C.
Cell lines and proliferation studies
The human embryonal carcinoma cell line NT2/D1 was derived from a xenograft of TERA-2 cells (Andrews, 1984) . The RA-resistant line NT2/D1-R1 was derived from NT2/D1 cells by mutagenization with N-methyl-nitro-nitrosoguanidine and selection in increasing RA dosages (Moasser et al., 1996) . Cells were cultured in DMEM media as previously described (Spinella et al., 1998; Andrews, 1984) .
Proliferation studies were conducted with NT2/D1 and NT2/D1-R1 cells treated with varying dosages of 4HPR. These experiments were carried out in a 6-well tissue culture plate containing 2 ml media supplemented with DMSO or 4HPR at desired dosages. Cells were harvested by trypsinization and were counted using a hemocytometer and trypan blue staining to score for viability on days 1 through 5. The eect of RA on growth of NT2/D1 cells was studied by ®rst culturing cells in desired RA dosages or DMSO vehicle for 5 days. Cells were harvested, counted on day 5 using a hemacytometer and re-seeded and treated with the desired vehicle or RA dosages. Viable cells were quantitated on days 7, 9, 11 and 13 using a hemacytometer and trypan blue dye exclusion staining. Viable cells were measured as the percentage of viable cells present in the DMSO-treated controls.
Immunophenotypic analysis and apoptosis assay
Dierentiation of NT2/D1 and NT2/D1-R1 cells was assessed using the neuronal marker A2B5 monoclonal antibody and analysis in indirect¯ow cytometry, as previously described (Kurie et al., 1993; Spinella et al., 1998) . Fluorescence of dierentiation positive cells was measured on a Becton Dickson FACScan¯ow cytometer equipped with CellQuest software.
The percentages of cells that had undergone apoptosis were measured using an in situ terminal deoxynucleotidyl transferase (TdT) assay (Boehringer Mannheim, IN, USA), as described (Nason-Burchenal et al., 1998) . Apoptosis was independently con®rmed in these cells by the appearance of DNA fragmentation. Apoptosis induced DNA fragmentation of 4HPR treated NT2/D1 and NT2/D1-R1 cells was analysed by gel electrophoresis. Brie¯y, NT2/D1 and NT2/D1-R1 cells were treated with DMSO vehicle or 4HPR at the desired dosages for 72 h. Floating cells were collected and adherent cells were washed with phosphate buered saline (PBS) and harvested following trypsinization. Equal numbers of adherent cells were combined with¯oating cells and lysed, as previously described (Park and Patek, 1997) . Genomic DNA was phenol-chloroform extracted, precipitated, electrophoresed at 36 V in a 2% agarose gel, stained with ethidium bromide and photographed.
Plasmid construction and transient transfection
The pSG5-hRARg1 plasmid was provided by Dr P Chambon (INSERM, France). The pSG5-hRARg2 plasmid was constructed by amplifying the unqiue NH 2 -terminus of human RARg2 (forward primer: 5'-TGCCGAAGCACCCA-GATAAG-3'; reverse primer: 5'-GAAGGTCATGGTGTC-CTGCTC-3') which contained a common and unique EcoRV site for both RARg1 and RARg2. The ampli®ed fragment was cloned into a pCRII vector (Invitrogen, Carlsbad, CA, USA) and excised with EcoRI restriction endonuclease. The EcoRI fragment was then cloned into an EcoRI restricted pSG5 vector which was subsequently cleaved with EcoRV and StuI. The EcoRV ± StuI fragment containing the NH 2 -terminus of RARg2 was then ligated to the EcoRV and StuI restricted pSG5-hRARg1 fragment replacing the RARg1 NH 2 -terminus. The presence of the RARg2 NH 2 -terminus was con®rmed by DNA sequencing.
The hRARg2P-luc plasmid was constructed using an ampli®ed fragment of the RARg2 promoter derived from NT2/D1 or NT2/D1-R1 genomic DNA (forward primer: 5'-CCCCACCCGGTACAACAGATT-3'; reverse primer: 5'-AACTGGGTGCTGGAAACACCAA-3'). The fragment was cloned into the pCRII vector (Invitrogen, CA, USA) and subsequently excised with KpnI and XhoI restriction endonucleases and the fragment was gel puri®ed. The fragment was then ligated to the KpnI and XhoI restricted pGL3-Basic vector (Promega, WI, USA). DNA sequencing and restriction fragment length polymorphism (RFLP) were employed to analyse the clone of RARg2 promoter in the plasmid construct.
Transient transfection experiments were performed using the previously described calcium phosphate precipitation method (Spinella et al., 1998) . Brie¯y, cells were seeded 1 day before transfection at a density of 4 ± 4.5610 5 cells per well in a 6-well tissue culture plate containing 2 ml media. Two hundred ml of transfection solution containing 3.5 mg of DNA were aliquoted into the desired tissue culture plates and then incubated for 14 ± 16 h. The DNA/media were then removed by aspiration and cells were washed twice with PBS before adding 2 ml of media supplemented with DMSO or with the desired retinoid. Cells were incubated with the appropriate retinoid for 24 h (for hRARg2P-luc reporter) or 48 h (for ®broblast growth factor 4 (FGF4)-CAT reporter) before harvesting for luciferase or CAT and b-galactosidase assays using reporter lysis buer (Promega, Madison, WI, USA), and standard techniques.
Semi-quantitation of RARg1 and RARg2 mRNA by RT ± PCR Expression levels of RARg1 versus RARg2 mRNAs in NT2/ D1 and NT2/D1-R1 cells treated with 10 mM RA or 1.5 mM 4HPR were measured by the RT ± PCR assay method. Total cellular RNA was isolated at various times after treatment with RA or 4HPR using a single-step simultaneous isolation method for RNA and DNA (Chromczynski, 1993) . cDNA was synthesized from total RNA using SuperScript II RNase H 7 reverse transcriptase and random primers, according to the manufacturer's recommended procedure (GIBCO ± BRL, MD, USA). Ampli®cation of cDNA for RARg1 and RARg2 was accomplished with a forward primer for RARg1: 5'-CACCAATAAGGAGCGACTCTTT-3'; and for RARg2: 5'-GCGATGTACGACTGTATGGAAA-3'; and a common reverse primer for both RARg species: 5'-GACACGTGTA-CACCATGTTCTT-3', generating ampli®cation products of 374 and 349 bp, respectively. As a control, human b-actin mRNA was ampli®ed from the same cDNA using a forward primer (5'-GCGGGAAATCGTGCGTGACA-3') and a reverse primer (5'-AAGGAAGGCTGGAAGAGTGC-3') to produce a PCR fragment of 183 bp. Ampli®cations were performed in 50 ml of 16PCR buer (16.6 mM ammonium sulfate; 67 mM Tris-HC1, pH 8.8 at 258C; 10 mM bmercaptoethanol; 6.7 mM EDTA; and 170 mg/ml BSA) containing 10% glycerol, 0.4 mM forward primer and reverse primer, 0.3 mM each of deoxynucleotide triphosphate and 1.25 units of Taq polymerase. Each ampli®cation reaction was supplemented with MgC1 2 (4, 2 and 3 mM for RARg1, RARg2 and b-actin, respectively). Assuming 100% eciency in the reverse transcription step, 500 ng of cDNA was used to amplify RARg1 and RARg2, 125 ng of cDNA was used to amplify b-actin. Experiments were performed to determine the optimal number of cycles that would yield linear phase of ampli®cation. Ampli®cation reactions were performed with an initial denaturation step at 968C for 2 min, followed by 22 or 27 cycles (for b-actin and RARg species, respectively) consisting of a denaturation step at 958C for 20 s, an annealing step at 578C for 20 s, and an extension step at 728C for 30 s with an additional 5 min at 728C in the last cycle of ampli®cation using a PTC-200 DNA Engine Thermocycler (MJ Research Inc., MA, USA). PCR products were resolved on a 1.5% agarose gel which was stained with ethidium bromide and images were obtained with a Bio-Rad Gel Doc 1000 system equipped with the Molecular Analyst/Macintosh data analysis software (Bio-Rad Laboratories, CA, USA). The intensity of the PCR product bands were quanti®ed using a Bio-Imaging Analyzer BAS1000 MacBAS (Fuji Photo Film Co., Ltd). Relative levels of RARg1 and RARg2 mRNAs were quanti®ed by normalizing the intensity of the obtained RARg PCR product species with the signal intensity obtained for the b-actin PCR product from the same RNA aliquot.
